TSC2 and angiomyolipoma: Two of the three tested sets had verifiable TSC2 mutations–the murine TTJ and human angiomyolipoma 621 cells–which allowed us to compare a TSC2-inactive (TSC2-) to a TSC2-active (Tsc2+) state.